Pentixapharm Holding AG Advances with PentixaFor in Phase 3

Pentixapharm Holding AG, under the guidance of NuWays AG, is making significant strides with its lead diagnostic agent, PentixaFor. Currently poised to enter Phase 3, the company has secured its financial position following a successful capital raise. The funding was anchored by Eckert Wagniskapital, bringing the company’s pro forma cash to approximately €25 million.

The Phase 3 study, PANDA, for PentixaFor is set to commence in the latter half of 2026. This advancement marks a critical step as it addresses essential diagnostics in the field of radiopharma, specifically targeting an unmet need within the PA pathway. PA affects nearly 30 million individuals in the US and Europe.

Pentixapharm's objective is to replace current invasive diagnostic procedures with PET/CT scans, leveraging the expanding nuclear medicine infrastructure. The strengthened cash position strategically places the company for potential commercial partnerships as early as 2027.